LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Search

Avita Therapeutics Inc

Fermé

3.72 9.73

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.66

Max

3.76

Chiffres clés

By Trading Economics

Revenu

3.9M

-9.9M

Ventes

-96K

18M

Marge bénéficiaire

-53.86

Employés

260

EBITDA

4M

-8.1M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+93.63% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-39M

102M

Ouverture précédente

-6.01

Clôture précédente

3.72

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Avita Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 nov. 2025, 21:36 UTC

Résultats

Australia's ANZ Bank Posts 10% Drop in Annual Profit -- Update

9 nov. 2025, 21:22 UTC

Résultats

Australia's ANZ Bank Posts 10% Drop in Annual Profit

10 nov. 2025, 00:00 UTC

Market Talk

India Inflation Poised to Hit New Low -- Market Talk

9 nov. 2025, 23:47 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

9 nov. 2025, 23:35 UTC

Market Talk

Gold Edges Higher Amid Signs of U.S. Economic Weakness -- Market Talk

9 nov. 2025, 21:05 UTC

Résultats

ANZ FY Total Operating Expenses A$12.88B Vs. A$11.465B Pro Forma>ANZ.AU

9 nov. 2025, 21:04 UTC

Résultats

ANZ FY Operating Expenses A$11.85B Ex-Significant Items>ANZ.AU

9 nov. 2025, 21:03 UTC

Résultats

ANZ 2H Net Interest Margin 1.54% Vs. 1.56% in 1H>ANZ.AU

9 nov. 2025, 20:49 UTC

Résultats

ANZ FY Australia Retail Deposits Up 6% on Year>ANZ.AU

9 nov. 2025, 20:49 UTC

Résultats

ANZ FY Australia Home Loan Lending Up 5% on Year>ANZ.AU

9 nov. 2025, 20:45 UTC

Résultats

ANZ FY Average Customer Deposits A$760.8B Vs. A$669.4B>ANZ.AU

9 nov. 2025, 20:45 UTC

Résultats

ANZ FY Average Gross Loans & Advances A$833.6B Vs. A$733.8B>ANZ.AU

9 nov. 2025, 20:42 UTC

Résultats

ANZ FY Results Include Full-Year Benefit of Suncorp Bank Acquisition>ANZ.AU

9 nov. 2025, 20:42 UTC

Résultats

ANZ FY Net Interest Margin 1.55% Vs. 1.57%>ANZ.AU

9 nov. 2025, 20:41 UTC

Résultats

ANZ FY Common Equity Tier 1 Ratio 12.0% Vs. 12.2%>ANZ.AU

9 nov. 2025, 20:41 UTC

Résultats

ANZ FY Net Profit Includes A$1.11B of Notable Items>ANZ.AU

9 nov. 2025, 20:39 UTC

Résultats

ANZ FY Credit Impairment Charge A$441M Vs. A$406M>ANZ.AU

9 nov. 2025, 20:39 UTC

Résultats

ANZ FY Rev A$22.19B Vs. A$20.55B >ANZ.AU

9 nov. 2025, 20:38 UTC

Résultats

ANZ Keeps Dividend at A$0.83 >ANZ.AU

9 nov. 2025, 20:38 UTC

Résultats

ANZ FY Cash Profit A$5.79B Vs. A$6.725B>ANZ.AU

9 nov. 2025, 20:38 UTC

Résultats

ANZ FY Net A$5.89B Vs. Net A$6.535B >ANZ.AU

8 nov. 2025, 13:10 UTC

Acquisitions, Fusions, Rachats

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 nov. 2025, 03:50 UTC

Acquisitions, Fusions, Rachats

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 nov. 2025, 03:41 UTC

Acquisitions, Fusions, Rachats

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 nov. 2025, 03:07 UTC

Acquisitions, Fusions, Rachats

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 nov. 2025, 22:36 UTC

Résultats

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov. 2025, 22:22 UTC

Résultats

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov. 2025, 22:03 UTC

Résultats

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov. 2025, 22:03 UTC

Résultats

Constellation Software 3Q Net $210M >CSU.T

7 nov. 2025, 22:03 UTC

Résultats

Constellation Software 3Q EPS $9.89 >CSU.T

Comparaison

Variation de prix

Avita Therapeutics Inc prévision

Objectif de Prix

By TipRanks

93.63% hausse

Prévisions sur 12 Mois

Moyen 7.3 USD  93.63%

Haut 14 USD

Bas 3 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

5 ratings

3

Achat

1

Maintien

1

Vente

Score Technique

By Trading Central

8.83 / 9.77Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
help-icon Live chat